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Approximately 1 in every 600 women attending breast-screening programmes in the United Kingdom is diagnosed with breast
carcinoma in situ (BCIS). However, there is little information on the occurrence of subsequent cancers (other than second
breast cancers) in these women. We investigated the occurrence of invasive cancers in 12 836 women diagnosed with BCIS in
southeast England between 1971 and 2003, using data from the Thames Cancer Registry. A greater than expected number of
subsequent cancers was found for two sites: breast (standardised incidence ratio (SIR) 1.96; 95% confidence interval (CI) 1.79–2.14)
and corpus uteri (SIR 1.42; 95% CI 1.11–1.78). For subsequent ipsilateral breast cancer in those treated with breast conservation, the
excess was independent of the time since diagnosis of BCIS, whereas for subsequent contralateral breast cancer, there was a steady
decline in excess over time. For subsequent uterine cancer, the excess became statistically significant only at 45 years after BCIS
diagnosis, consistent with a treatment effect. This was further supported by Cox regression anaysis: the risk of subsequent uterine
cancer was significantly increased in women receiving hormonal therapy compared with those not receiving it, with a hazard ratio of
2.97 (95% CI 1.84–4.80).
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Currently, approximately 1 in every 600 women attending breast-
screening programmes in the United Kingdom is diagnosed with
breast carcinoma in situ (BCIS). This amounted to almost 3000 cases
in 2004–2005 (NHS Cancer Screening Programmes, 2006). The most
common form of treatment is lumpectomy, with or without
radiotherapy, although women with a more diffuse pattern of BCIS
may undergo mastectomy. A number of previous studies have
focused on the risk of second breast cancer following a diagnosis of
BCIS (Habel et al, 1997; Wa¨rnberg et al, 2000; Claus et al, 2003; Levi
et al, 2005; Rawal et al, 2005), with estimates of relative risk
generally of the order of two- to fivefold. Few studies have looked at
the occurrence of subsequent invasive cancers at other sites (Ward
et al, 1992; Franceschi et al, 1998; Soerjomataram et al, 2006), and
these were based on relatively small numbers of cases.
In the current population-based study, we have investigated the
occurrence of subsequent invasive cancers in a very large series of
unselected women with BCIS in southeast England. We have also
examined the relationship between treatment for BCIS and the
development of subsequent cancers.
MATERIALS AND METHODS
All recorded cases of BCIS (ICD10 code D05) diagnosed in women
between 1971 and 2003 were extracted from the Thames Cancer
Registry (TCR) database. The TCR is a population-based registry
covering London and a large part of southeast England. Patients
with any other cancers diagnosed prior to, or at the same time as,
BCIS were excluded in order to avoid confounding the sequelae of
BCIS with those of other cancers, particularly breast cancer. The
occurrence of subsequent cancers was analysed by calculating
the standardised incidence ratio (SIR) for each cancer site. This is
the ratio of the observed number of cancers at that site divided
by the number expected in the general population, calculated by
multiplying time at risk by age/calendar period-matched incidence
rates for women in southeast England. For each case, person-years
were calculated from date of diagnosis to the end of 2004, date
of death, date of last known follow-up or date of diagnosis of
subsequent cancer, whichever was earlier. Ipsilateral and contral-
ateral subsequent breast cancers were considered separately. When
analysing ipsilateral subsequent breast cancer, follow-up was
truncated at the date of mastectomy if this had been performed.
Information on radiotherapy and hormonal therapy received
within 6 months of diagnosis was also available on the database.
Although precise details of the type of hormonal therapy were
unavailable, the use of tamoxifen is likely to predominate. The
effects of treatment on the occurrence of subsequent cancers were
explored by applying Cox regression models with age at diagnosis
of BCIS (stratified into 5-year age groups), radiotherapy and
hormonal therapy as covariates. Results for a given mode of
treatment were expressed as the hazard ratio (HR) in those
with a record of receiving that treatment vs those with no such
record, adjusted for age and the receipt or otherwise of the other
treatment mode.
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RESULTS
A total of 14 329 cases of BCIS were extracted from the database. Of
these, 23 were excluded as having a recorded date of diagnosis that
was the same as the date of death, and a further 1046 cases were
excluded as having a prior or synchronous cancer. An additional
424 patients who were recorded as receiving chemotherapy were
also excluded, as it is likely that these patients were wrongly
classified as chemotherapy was not a normal component of
treatment for BCIS during the period of the study. This left a total
of 12 836 cases for analysis. Table 1 shows the characteristics of the
patients included in the study. The majority (86%) of the in situ
cancers were intraductal BCIS, 5% were lobular BCIS and the
remainder were of other or mixed morphological subtypes. The
mean age at diagnosis was 57 years. Overall, 3880 patients (30.2%)
had a record of radiotherapy treatment and 3064 (23.9%) had a
record of hormonal therapy. Of the patients who underwent
breast-conserving surgery, 42% had a record of treatment with
radiotherapy.
Table 2 shows the observed and expected numbers of
subsequent invasive cancers at a number of major sites. A greater
than expected number of subsequent occurrences of cancer was
found for two sites: breast (C50) and corpus uteri (C54).
Standardised incidence ratios were 1.96 for breast cancer (95%
confidence interval (CI) 1.79–2.14) and 1.42 for uterine cancer
(95% CI 1.11–1.78). There was a reduced incidence of cancers of
the pancreas (SIR 0.59; 95% CI 0.37–0.90) and lung (SIR 0.75; 95%
CI 0.61–0.92), and of cancers at ‘other’ sites (SIR 0.52; 95% CI
0.41– 0.66).
Table 3 shows the SIRs for these two sites by time since
diagnosis of BCIS, and also separately for subsequent ipsilateral
and contralateral breast cancers. The overall SIRs for subsequent
ipsilateral and contralateral breast cancers were 2.37 (95% CI
2.07– 2.70) and 1.72 (95% CI 1.53– 1.93), respectively. For
subsequent ipsilateral breast cancer, the excess was fairly constant,
with SIRs of 2.24, 2.55 and 2.27 at times 0 –1, 1–5 and 45 years
after BCIS diagnosis, respectively. For subsequent contralateral
breast cancer, there was a steady decline in the excess over time,
with SIRs of 3.00, 2.07 and 1.38, respectively, in these three time
periods. For subsequent cancer of the uterus, the excess became
statistically significant only at 45 years after BCIS diagnosis (SIR
1.58; 95% CI 1.18– 2.07).
In general, results were similar when looking separately at
patients diagnosed with ductal carcinoma in situ (DCIS) or lobular
carcinoma in situ (LCIS) (results not shown). However, in the first
year post-diagnosis, there was a significant excess of subsequent
ipsilateral breast cancers in women diagnosed with LCIS (SIR 8.06;
95% CI 2.62–18.82), but not for DCIS (SIR 1.51; 95% CI 0.80–2.58).
The results of the Cox regression analysis are shown in Table 4.
The risk of subsequent uterine cancer was significantly increased
in women with a record of hormonal therapy (compared with
those without), with an HR of 2.97 (95% CI 1.84–4.80). The risk of
subsequent breast cancer was decreased in women with a record of
radiotherapy (HR 0.73; 95% CI 0.60–0.89); this reduction in risk
was due solely to a decreased risk of subsequent ipsilateral breast
cancer (HR 0.40; 95% CI 0.29–0.55). There was no significant
reduction in the risk of subsequent contralateral breast cancer in
women with a record of radiotherapy. Including period of
diagnosis and morphological type as additional factors in the
model had no significant effect on the estimated HRs.
A separate analysis restricted to women in the age range of 50–
64 years eligible for breast screening showed essentially the same
results (data not shown). In addition, stratifying the analysis into
pre- and post-screening periods (1971– 1989 vs 1990–2003)
produced similar results with respect to subsequent invasive
breast cancer. There was no significant excess of uterine cancer in
the earlier period, but this was due to the small number of patients
receiving hormonal therapy prior to mid 1980s/early 1990s.
DISCUSSION
We have found an excess of subsequent cancers of the breast and
corpus uteri following a diagnosis of BCIS. For subsequent uterine
cancer, the excess became statistically significant only at 45 years
after BCIS diagnosis, consistent with a treatment effect. This was
Table 1 Patient characteristics
No. of patients % of patients
Age at diagnosis (years)
o45 1764 13.7
45–49 1611 12.6
50–54 2568 20.0
55–59 2133 16.6
60–64 1920 15.0
X65 2840 22.1
Period of diagnosis
1971–1974 971 7.6
1975–1984 2360 18.4
1985–1994 3892 30.3
1995–2003 5613 43.7
Morphological type
Ductal 11 052 86.1
Lobular 681 5.3
Other/mixed 1103 8.6
Surgery
Total mastectomy 4713 36.7
Partial mastectomy 764 6.0
Lumpectomy 4991 38.9
Other surgery 632 4.9
None 1736 13.5
Radiotherapy
Yes 3880 30.2
No 8956 69.8
Hormonal therapy
Yes 3064 23.9
No 9772 76.1
Total cases 12 836
Table 2 Occurrence of invasive cancers at specific sites subsequent to
breast carcinoma in situ
Site Observed Expected SIR 95% CI
Head and neck 19 25.03 0.76 0.46–1.19
Oesophagus 22 22.85 0.97 0.60–1.46
Stomach 26 32.82 0.79 0.52–1.16
Colorectal 130 147.93 0.88 0.73–1.04
Pancreas 22 37.20 0.59 0.37–0.90
Lung 101 133.92 0.75 0.61–0.92
Malignant melanoma 14 21.80 0.64 0.35–1.08
Breast 512 261.44 1.96 1.79–2.14
Cervix uteri 12 20.39 0.59 0.30–1.03
Corpus uteri 74 52.14 1.42 1.11–1.78
Ovary 49 59.81 0.82 0.61–1.08
Kidney 16 16.02 1.00 0.57–1.62
Bladder 22 30.13 0.73 0.46–1.11
Non-Hodgkin’s lymphoma 24 35.56 0.67 0.43–1.00
Multiple myeloma 11 16.00 0.69 0.34–1.23
Leukaemia 20 24.93 0.80 0.49–1.24
Othersa 72 138.28 0.52 0.41–0.66
All sitesa 1146 1076.25 1.06 1.00–1.13
CI¼ confidence interval; SIR¼ standardised incidence ratio. aExcluding non-melano-
ma skin cancers.
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confirmed by Cox regression analysis: the risk of subsequent
uterine cancer was significantly increased in women with a record
of hormonal therapy, with an HR of 2.97 (95% CI 1.84–4.80).
Increased occurrence of breast cancer following BCIS has been
shown in a number of previous studies from around the world:
from Sweden (Wa¨rnberg et al, 2000; Rawal et al, 2005); Switzerland
(Franceschi et al, 1998; Levi et al, 2005); The Netherlands
(Soerjomataram et al, 2006); and the United State of America
(Ward et al, 1992; Habel et al, 1997; Claus et al, 2003).
Soerjomataram et al (2006) also found an increased occurrence
of skin cancer (SIR 1.7; 95% CI 1.1–2.6) following BCIS, whereas
Ward et al (1992) found that (apart from breast cancer) colorectal,
cervical and endometrial cancers were the most prevalent in BCIS
patients. On the other hand, Franceschi et al (1998) found no
excess risk at any cancer site other than the breast.
Soerjomataram et al (2006) studied subsequent ipsilateral and
contralateral breast cancers separately, and found the increased
risks to be similar (SIR for ipsilateral 1.9; contralateral 2.0)
– although each of these figures was based on a per-person rather
than per-breast calculation and should therefore be doubled in
order to be directly comparable with our SIR estimates.
The very high SIR (3.00; 95% CI 2.17–4.04) observed for
subsequent contralateral breast cancer in the first year after BCIS
diagnosis may be a manifestation of co-existing disease, or may
result from the extra surveillance around the time of treatment for
the first breast cancer, intense medical follow-up or self-observation
of the patient – resulting in either detection or lead-time bias. The
fact that detection bias is in operation is further indicated by the
high risk of ipsilateral cancer (SIR 8.06) in patients with LCIS during
the first year of follow-up, as LCIS has traditionally been thought to
be a marker for high risk of multifocal and contralateral disease
(Frykberg et al, 1987; Page et al, 1991; Chuba et al, 2005).
The SIR values we found for subsequent breast and uterine
cancers are similar to those following invasive breast cancer from
an earlier study on the same population (Evans et al, 2001). This
similarity was also seen in the studies by Soerjomataram et al
(2006) and Claus et al (2003).
It is known from randomised controlled trials that radiotherapy
after breast-conserving surgery for BCIS reduces recurrences in the
ipsilateral breast (Fisher et al, 1993; Fisher et al, 1998; Julien et al,
2000; Houghton et al, 2003; Bijker et al, 2006; Emdin et al, 2006;
Ringberg et al, 2007). We also found this protective effect of
radiotherapy on the subsequent development of invasive cancer
in the ipsilateral breast (HR 0.40; 95% CI 0.29– 0.55). This HR
is similar to those reported from the clinical trials. Thus, the
well-studied effects of radiotherapy appear to hold true in an
observational setting. However, our findings are in contrast with
those of Soerjomataram et al (2006), who found (also in an
observational setting) that both ipsilateral and contralateral
invasive breast cancer risks were slightly higher in BCIS patients
who received radiotherapy.
In our study, we found a significant effect of hormonal therapy
on the subsequent risk of uterine cancer in women diagnosed with
BCIS, with those who received this form of treatment being three
times more likely to develop cancer of the uterus than those who
did not. This was not offset by any significant reduction in the risk
of developing subsequent invasive breast cancer (HR 1.01; 95% CI
0.82– 1.25).
A number of previous studies have demonstrated a link between
hormonal treatment for invasive breast cancer and the develop-
ment of uterine or endometrial cancer (Khandekar et al, 1978;
Hardell, 1988; Fornander et al, 1989; Atlante et al, 1990; Gusberg,
1990; Mathew et al, 1990; Andersson et al, 1991; Fisher et al, 1994;
Rubino et al, 2003). However, it is generally accepted that for
Table 4 HRs and 95% CIs for subsequent cancer in relation to type of
treatment
Type of treatment
Site Radiotherapy Hormone therapy
Uterus
Pyrsa 41 554 26 866
nb 22 34
HRc 0.83 2.97
CI 0.50–1.37 1.84–4.80
Breast
All
Pyrsa 34 105 22 834
nb 145 120
HRc 0.73 1.01
CI 0.60–0.89 0.82–1.25
Ipsilateral
Pyrsa 27 803 19 387
nb 49 65
HRc 0.40 1.20
CI 0.29–0.55 0.89–1.61
Contralateral
Pyrsa 40 408 26 281
nb 96 55
HRc 1.07 0.85
CI 0.84–1.37 0.63–1.15
CI¼ confidence interval; HR¼ hazard ratio; Pyrs¼ person-years. aTotal person-years
in group receiving treatment of specified type. bNumber of occurrences of
subsequent cancer in group receiving treatment. cHR for treatment recorded vs
not recorded, adjusted for 5-year age group and other treatment mode.
Table 3 Occurrence of invasive cancers of the breast and uterus
subsequent to breast carcinoma in situ (by time since diagnosis)
Years since diagnosis
Site 0–1 1–5 45 Total
Uterus
Pyrs 12 736 42 110 73 850 128 696
Obs 6 16 52 74
Exp 4.11 15.07 32.96 52.14
SIR 1.46 1.06 1.58 1.42
CI 0.54–3.18 0.61–1.72 1.18–2.07 1.11–1.78)
Breast
All
Pyrs 10 467 33 671 53 206 97 344
Obs 66 189 257 512
Exp 24.57 83.59 153.28 261.44
SIR 2.69 2.26 1.68 1.96
CI 2.08–3.42 1.95–2.61 1.48–1.89 1.79–2.14
Ipsilateral
Pyrs 8388 26 106 35 250 69 744
Obs 23 86 117 226
Exp 10.25 33.73 51.47 95.45
SIR 2.24 2.55 2.27 2.37
CI 1.42–3.37 2.04–3.15 1.88–2.72 2.07–2.70
Contralateral
Pyrs 12 547 41 235 71 162 124 944
Obs 43 103 140 286
Exp 14.32 49.86 101.81 165.99
SIR 3.00 2.07 1.38 1.72
CI 2.17–4.04 1.69–2.51 1.16–1.62 1.53–1.93
CI¼ confidence interval; Exp¼ expected number; Obs¼ observed number;
Pyrs¼ person-years; SIR¼ standardised incidence ratio.
BCIS and second cancers
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women with invasive breast cancer, the benefits of hormonal
treatment, such as tamoxifen, outweigh the associated risks (Gail
et al, 1999).
In the NSABP B-24 study, Fisher et al (1999) compared
lumpectomy plus radiation therapy with lumpectomy, radiation
therapy and tamoxifen treatment. They found that the risk of
ipsilateral breast cancer was lower in the tamoxifen group. In
contrast, Houghton et al (2003) in the UK randomised trial found
that ipsilateral invasive disease was not reduced by tamoxifen, and
concluded that ‘there is little evidence for the use of tamoxifen in
these women’.
We found significantly lower than expected numbers of lung
and pancreatic cancers following a diagnosis of BCIS as well as in
the group of ‘other’ cancers. This has not been reported in other
studies. The incidence of breast cancer and the uptake of
mammographic screening are known to be related to the socio-
economic status, and it is likely that the women in our study are
more affluent and generally more health conscious, with lower
than average rates of smoking.
The major strengths of our study are its population-based
design, the large number of patients and the length of follow-up.
However, it also has a number of limitations. The findings on the
incidence of second primary cancers are based on cancer registry
data, which contain limited and incomplete treatment information
largely confined to initial management and lacking in detail of
specific drugs, radiation doses and radiation fields. Also, there may
be underreporting of second cancers in those who leave the
registry catchment area. In the majority of such cases, the registry
would neither be informed of the patient’s emigration nor receive
notification of subsequent cancers. This would lead to an
underestimation of the risk of subsequent cancer, and hence the
quoted SIR values relating to excess risk will tend to be erroneous
on the conservative side. In addition, as the data were extracted in
2005, cancer incidence till the end of 2004 would still be
incomplete by a few percent. Again, this would tend to lead to
an underestimation of SIRs, although this problem would be
restricted to the short-term estimates.
There is also a possibility of under-ascertainment of treatment
in the TCR database, as information on treatment more
than 6 months after diagnosis is not recorded. This is more
likely to be of importance in relation to the recording of
radiotherapy, as waiting times for radiotherapy are known to
have increased in recent years (Robinson et al, 2005; Jack et al,
2007). However, any misclassification would result in a dilution
of the difference between the treated and untreated groups,
and hence any reported estimates of treatment effects would
be conservative. A previous study on the same database
(Roychoudhuri et al, 2004), looking at malignancies following
radiotherapy for invasive breast cancer, showed an increase in
myeloid leukaemia consistent with other studies, suggesting that
the treatment data are reliable.
The quality and completeness of the recording of BCIS have
been variable over the period studied. There was an increase in the
numbers in mid 1990s, corresponding to an increased rate of
detection following the introduction of the national breast-
screening programme. Since then, rates have continued to rise,
with the overall age-standardised rate for 2003 being approxi-
mately 13 per 100 000 women. Our identification of BCIS cases was
based on patient pathology reports. As a result of changes over
time in the histological classification and diagnosis of BCIS, it is
possible that some of our patients may have had invasive breast
cancer that was missed on diagnosis, but we would expect the
number of such cases to be small.
There have also been significant changes in treatment for BCIS
over the period of the study. Cox regression analysis indicates that
after allowing for these changes in treatment over time, the period
of diagnosis was not independently related to subsequent risk of
cancer, that is, there is no significant effect of period over and
above the associated treatment effects.
Although we have allowed for the effects of curative mastec-
tomies by analysing ipsilateral and contralateral subsequent breast
cancers separately, our data set may still contain women who
underwent prophylactic removal of the contralateral breast, which
we were unable to allow for. However, the number of such women
is likely to be small and would have minimal effect on the
calculation of risk estimates.
In many women, BCIS is detected at screening. Our data show
that such women are at a moderately increased risk of a
subsequent contralateral invasive breast cancer, a greater risk of
ipsilateral invasive breast cancer in those with a preserved breast
(especially if radiotherapy is not given) and a risk of uterine cancer
associated with hormonal treatment. However, all three can be
managed – the first by surveillance to detect and treat early, the
second by radiotherapy and the third by the limitation of the
administration of tamoxifen to those patients for whom it is really
indicated.
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